Ferrer International 
Welcome,         Profile    Billing    Logout  
 11 Products   46 Diseases  11 Products   16 Trials   986 News 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wakix (pitolisant) / Ferrer International, Paragon Biosci, Aculys Pharma
NCT05581576: Pitolisant in Refractory Restless Legs Syndrome

Recruiting
4
18
US
Pitolisant, Wakix
William Ondo, MD, Harmony Biosciences, LLC
Restless Legs Syndrome
05/23
05/23
2009-013885-14: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.

Ongoing
3
148
Europe
Pitolisant, BF2.649,
BIOPROJET
Excessive daytime sleepiness in Parkinson?s DiseaseSomnolencia diurna excesiva en la enfermedad de Parkinson.
 
 
NCT02611687 / 2013-001506-29: Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period

Completed
3
110
Europe, RoW
pitolisant, BF2.649, Placebo
Bioprojet
Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy
04/21
06/25
NCT05223166: A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA

Completed
3
240
RoW
Pitolisant, Placebo oral tablet
Citrine Medicine Limited
Excessive Daytime Sleepiness
07/23
07/23
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia
09/23
09/23
NCT06366464: A Study of Pitolisant in Patients With Prader-Willi Syndrome

Recruiting
3
134
Europe, US, RoW
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences Management, Inc.
Prader-Willi Syndrome
07/26
07/27
NCT05458128: A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients with Idiopathic Hypersomnia

Active, not recruiting
3
128
US
Pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia, Excessive Daytime Sleepiness
08/25
12/25
NCT04257929: A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Hourglass Jan 2022 - Jun 2022 : Efficacy and safety data for treatment of EDS in patients with Prader Willi syndrome
Active, not recruiting
2
65
US
Pitolisant oral tablets, Placebo oral tablet
Harmony Biosciences, LLC
Prader-Willi Syndrome
08/22
09/28
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Hourglass Jul 2022 - Dec 2022 : Efficacy and safety data for treatment of EDS in patients with Myotonic Dystrophy Type 1
Completed
2
30
Canada, US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences Management, Inc.
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
10/23
10/24
NCT05953389: Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

Recruiting
2
62
Europe
Pitolisant, BF2.649, Placebo
Bioprojet
Autism Spectrum Disorder
11/25
11/25
NCT04596267: Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers

Terminated
1
9
US
Pitolisant, wakix, Placebo
Boston Medical Center, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Alcohol Drinking
02/23
02/23
NCT07051252: An Open-Label Study of HBS-201 (Pitolisant Delayed-release)

Recruiting
1
40
US
HBS-201, pitolisant delayed-release (DR), pitolisant hydrochloride
Harmony Biosciences Management, Inc.
Narcolepsy
11/25
11/25
NCT03433131: Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

No Longer Available
N/A
US
Pitolisant, Wakix
Harmony Biosciences, LLC
Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
 
 
PEACE, NCT05849675: Pitolisant Effects on Affect and Cognition Exploratory Study ( Study)

Completed
N/A
58
Europe
Pitolisant 17.8 MG [Wakix], Placebo
University of Oxford
Anhedonia, Cognitive Function
02/24
05/24
NCT05536011: WAKIX® (Pitolisant) Pregnancy Registry

Recruiting
N/A
1329
US
Pitolisant, Wakix, Comparator Products, Modafinil/armodafinil, Sodium oxybate, Oxybate mixed salts, Solriamfetol, Methylphenidate, Amphetamines
Harmony Biosciences, LLC
Pregnancy Related, Narcolepsy
06/30
06/30
Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
2016-004884-38: Evaluation of the effectiveness of loxapine in agitated patients with personality disorder Evaluación de la eficacia de la loxapina en pacientes agitados con trastorno de personalidad

Ongoing
4
30
Europe
Inhalation powder, pre-dispensed, ADASUVE 9.1 mg inhalation powder, pre-dispensed
Vall d'Hebron University Hospital, Vall d'Hebron University Hospital
Acute pre/agitated patients with personality disorder Agitación en pacientes con trastorno de personalidad., Patients with personality disorder that arrive to the ER with an acute pre/agitation state Pacientes con trastorno de personalidad que acuden a urgencias en un estado de agitación o pre-agitación agudo., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT03513549: Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Recruiting
N/A
10000
US
Loxapine 10 MG, ADASUVE (loxapine) inhalation powder, NDA 022549
Alexza Pharmaceuticals, Inc., Pharmaceutical Research Associates
Agitation,Psychomotor
10/21
03/22
Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
2012-000746-36: Study to evaluate the absorption and safety of an antibiotic cream administered twice daily in patients, including children, with an skin infection called impetigo.

 
1
NA
Ozenoxacin, GF-001001-00,
Ferrer Internacional, S.A., Ferrer Internacional, S.A.
Impetigo
 
 
staccato alprazolam (AZ-002) / UCB
NCT05077904 / 2021-002686-18: A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Recruiting
3
350
Europe, Japan, US, RoW
Staccato alprazolam, UCB7538, Placebo
UCB Biopharma SRL
Stereotypical Prolonged Seizures
04/26
04/26
NCT05076617 / 2021-002637-42: A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Enrolling by invitation
3
300
Europe, Japan, US, RoW
Staccato alprazolam, UCB7538
UCB Biopharma SRL
Stereotypical Prolonged Seizures
11/28
11/28
NCT05626439: A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Completed
1
21
US
Staccato alprazolam, UCB7538, Oral alprazolam, Xanax
UCB Biopharma SRL
Healthy Participants
02/23
02/23
NCT07020988: A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Not yet recruiting
1
50
NA
Staccato Alprazolam, UCB7538, Midazolam, Diazepam
UCB Biopharma SRL
Healthy Participants
01/26
01/26
staccato fentanyl (AZ-003) / Ferrer International
NCT05531422: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Completed
2
60
RoW
Inhaled fentanyl aerosol, Placebo
Lee's Pharmaceutical Limited
Breakthrough Cancer Pain
03/23
04/23
NCT04713189: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

Not yet recruiting
1/2
96
NA
Inhaled fentanyl aerosol, Placebo
Lee's Pharmaceutical Limited
Breakthrough Cancer Pain
12/21
12/21
NCT06953453: A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

Not yet recruiting
1
100
RoW
Inhaled Fentanyl Aerosol, Fentanyl Citrate Injection
Lee's Pharmaceutical Limited
Cancer
07/26
08/26
Huntexil (pridopidine) / Prilenia
NCT04556656 / 2020-002822-10: PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Completed
3
499
Europe, Canada, US, RoW
Pridopidine, Placebo
Prilenia
Huntington Disease
03/23
03/24
NCT04615923: HEALEY ALS Platform Trial - Regimen D Pridopidine

Completed
2/3
163
US
Pridopidine, Matching Placebo
Merit E. Cudkowicz, MD, Prilenia Therapeutics
Amyotrophic Lateral Sclerosis
07/22
07/22
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
NCT06069934: A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
edaravone oral (FNP122) / Treeway
2022-003050-32: A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Ongoing
3
225
Europe
Edaravone, FAB122, Granules for oral solution in sachet
Ferrer Internacional, S.A., Ferrer Internacional, S.A.
Amyotrophic Lateral Sclerosis (ALS), ALS is a progressive and irreversible damage or degeneration of the nerve cells responsible for the movement of muscles., Diseases [C] - Nervous System Diseases [C10]
 
 
ADORE, NCT05178810 / 2020-003376-40: Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

Completed
3
313
Europe
FAB122, Placebo
Ferrer Internacional S.A., Julius Clinical, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
10/23
10/23
ADOREXT, NCT05866926 / 2022-003050-32: Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Terminated
3
201
Europe
FAB122
Ferrer Internacional S.A., Ferrer Internacional, S.A.
Amyotrophic Lateral Sclerosis
01/24
02/24
2021-003164-27: Evaluation of Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients Evaluatie van veiligheid, farmacodynamiek en farmacokinetiek van TW001 in Alzheimer patiënten

Ongoing
2
150
Europe
TW001 granules for oral solution, TEST, Granules for oral solution
Treeway TW001AD B.V., Treeway TW001AD B.V.
Alzheimer´s Disease (AD) Ziekte van Alzheimer, Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. De ziekte van Alzheimer is een hersenaandoening die langzaam het geheugen en de denkvaardigheden vernietigt, en uiteindelijk het vermogen om de eenvoudigste taken uit te voeren., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05323812 / 2021-003164-27: ASURE: Alzheimer Study Using oRal Edaravone

Completed
2
61
Europe, RoW
TW001, Edaravone, Placebo
Treeway B.V., Treeway TW001AD B.V.
Alzheimer Disease
12/24
12/24
apomorphine inhalational (AZ-009) / Ferrer International
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wakix (pitolisant) / Ferrer International, Paragon Biosci, Aculys Pharma
NCT05581576: Pitolisant in Refractory Restless Legs Syndrome

Recruiting
4
18
US
Pitolisant, Wakix
William Ondo, MD, Harmony Biosciences, LLC
Restless Legs Syndrome
05/23
05/23
2009-013885-14: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.

Ongoing
3
148
Europe
Pitolisant, BF2.649,
BIOPROJET
Excessive daytime sleepiness in Parkinson?s DiseaseSomnolencia diurna excesiva en la enfermedad de Parkinson.
 
 
NCT02611687 / 2013-001506-29: Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period

Completed
3
110
Europe, RoW
pitolisant, BF2.649, Placebo
Bioprojet
Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy
04/21
06/25
NCT05223166: A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA

Completed
3
240
RoW
Pitolisant, Placebo oral tablet
Citrine Medicine Limited
Excessive Daytime Sleepiness
07/23
07/23
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia
09/23
09/23
NCT06366464: A Study of Pitolisant in Patients With Prader-Willi Syndrome

Recruiting
3
134
Europe, US, RoW
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences Management, Inc.
Prader-Willi Syndrome
07/26
07/27
NCT05458128: A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients with Idiopathic Hypersomnia

Active, not recruiting
3
128
US
Pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia, Excessive Daytime Sleepiness
08/25
12/25
NCT04257929: A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Hourglass Jan 2022 - Jun 2022 : Efficacy and safety data for treatment of EDS in patients with Prader Willi syndrome
Active, not recruiting
2
65
US
Pitolisant oral tablets, Placebo oral tablet
Harmony Biosciences, LLC
Prader-Willi Syndrome
08/22
09/28
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Hourglass Jul 2022 - Dec 2022 : Efficacy and safety data for treatment of EDS in patients with Myotonic Dystrophy Type 1
Completed
2
30
Canada, US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences Management, Inc.
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
10/23
10/24
NCT05953389: Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

Recruiting
2
62
Europe
Pitolisant, BF2.649, Placebo
Bioprojet
Autism Spectrum Disorder
11/25
11/25
NCT04596267: Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers

Terminated
1
9
US
Pitolisant, wakix, Placebo
Boston Medical Center, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Alcohol Drinking
02/23
02/23
NCT07051252: An Open-Label Study of HBS-201 (Pitolisant Delayed-release)

Recruiting
1
40
US
HBS-201, pitolisant delayed-release (DR), pitolisant hydrochloride
Harmony Biosciences Management, Inc.
Narcolepsy
11/25
11/25
NCT03433131: Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

No Longer Available
N/A
US
Pitolisant, Wakix
Harmony Biosciences, LLC
Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
 
 
PEACE, NCT05849675: Pitolisant Effects on Affect and Cognition Exploratory Study ( Study)

Completed
N/A
58
Europe
Pitolisant 17.8 MG [Wakix], Placebo
University of Oxford
Anhedonia, Cognitive Function
02/24
05/24
NCT05536011: WAKIX® (Pitolisant) Pregnancy Registry

Recruiting
N/A
1329
US
Pitolisant, Wakix, Comparator Products, Modafinil/armodafinil, Sodium oxybate, Oxybate mixed salts, Solriamfetol, Methylphenidate, Amphetamines
Harmony Biosciences, LLC
Pregnancy Related, Narcolepsy
06/30
06/30
Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
2016-004884-38: Evaluation of the effectiveness of loxapine in agitated patients with personality disorder Evaluación de la eficacia de la loxapina en pacientes agitados con trastorno de personalidad

Ongoing
4
30
Europe
Inhalation powder, pre-dispensed, ADASUVE 9.1 mg inhalation powder, pre-dispensed
Vall d'Hebron University Hospital, Vall d'Hebron University Hospital
Acute pre/agitated patients with personality disorder Agitación en pacientes con trastorno de personalidad., Patients with personality disorder that arrive to the ER with an acute pre/agitation state Pacientes con trastorno de personalidad que acuden a urgencias en un estado de agitación o pre-agitación agudo., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT03513549: Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Recruiting
N/A
10000
US
Loxapine 10 MG, ADASUVE (loxapine) inhalation powder, NDA 022549
Alexza Pharmaceuticals, Inc., Pharmaceutical Research Associates
Agitation,Psychomotor
10/21
03/22
Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
2012-000746-36: Study to evaluate the absorption and safety of an antibiotic cream administered twice daily in patients, including children, with an skin infection called impetigo.

 
1
NA
Ozenoxacin, GF-001001-00,
Ferrer Internacional, S.A., Ferrer Internacional, S.A.
Impetigo
 
 
staccato alprazolam (AZ-002) / UCB
NCT05077904 / 2021-002686-18: A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Recruiting
3
350
Europe, Japan, US, RoW
Staccato alprazolam, UCB7538, Placebo
UCB Biopharma SRL
Stereotypical Prolonged Seizures
04/26
04/26
NCT05076617 / 2021-002637-42: A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Enrolling by invitation
3
300
Europe, Japan, US, RoW
Staccato alprazolam, UCB7538
UCB Biopharma SRL
Stereotypical Prolonged Seizures
11/28
11/28
NCT05626439: A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Completed
1
21
US
Staccato alprazolam, UCB7538, Oral alprazolam, Xanax
UCB Biopharma SRL
Healthy Participants
02/23
02/23
NCT07020988: A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Not yet recruiting
1
50
NA
Staccato Alprazolam, UCB7538, Midazolam, Diazepam
UCB Biopharma SRL
Healthy Participants
01/26
01/26
staccato fentanyl (AZ-003) / Ferrer International
NCT05531422: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Completed
2
60
RoW
Inhaled fentanyl aerosol, Placebo
Lee's Pharmaceutical Limited
Breakthrough Cancer Pain
03/23
04/23
NCT04713189: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

Not yet recruiting
1/2
96
NA
Inhaled fentanyl aerosol, Placebo
Lee's Pharmaceutical Limited
Breakthrough Cancer Pain
12/21
12/21
NCT06953453: A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

Not yet recruiting
1
100
RoW
Inhaled Fentanyl Aerosol, Fentanyl Citrate Injection
Lee's Pharmaceutical Limited
Cancer
07/26
08/26
Huntexil (pridopidine) / Prilenia
NCT04556656 / 2020-002822-10: PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Completed
3
499
Europe, Canada, US, RoW
Pridopidine, Placebo
Prilenia
Huntington Disease
03/23
03/24
NCT04615923: HEALEY ALS Platform Trial - Regimen D Pridopidine

Completed
2/3
163
US
Pridopidine, Matching Placebo
Merit E. Cudkowicz, MD, Prilenia Therapeutics
Amyotrophic Lateral Sclerosis
07/22
07/22
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
NCT06069934: A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
edaravone oral (FNP122) / Treeway
2022-003050-32: A study to investigate the safety of FAB122 in patients with Amyotrophic Lateral Sclerosis on the long term.

Ongoing
3
225
Europe
Edaravone, FAB122, Granules for oral solution in sachet
Ferrer Internacional, S.A., Ferrer Internacional, S.A.
Amyotrophic Lateral Sclerosis (ALS), ALS is a progressive and irreversible damage or degeneration of the nerve cells responsible for the movement of muscles., Diseases [C] - Nervous System Diseases [C10]
 
 
ADORE, NCT05178810 / 2020-003376-40: Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

Completed
3
313
Europe
FAB122, Placebo
Ferrer Internacional S.A., Julius Clinical, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
10/23
10/23
ADOREXT, NCT05866926 / 2022-003050-32: Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Terminated
3
201
Europe
FAB122
Ferrer Internacional S.A., Ferrer Internacional, S.A.
Amyotrophic Lateral Sclerosis
01/24
02/24
2021-003164-27: Evaluation of Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients Evaluatie van veiligheid, farmacodynamiek en farmacokinetiek van TW001 in Alzheimer patiënten

Ongoing
2
150
Europe
TW001 granules for oral solution, TEST, Granules for oral solution
Treeway TW001AD B.V., Treeway TW001AD B.V.
Alzheimer´s Disease (AD) Ziekte van Alzheimer, Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. De ziekte van Alzheimer is een hersenaandoening die langzaam het geheugen en de denkvaardigheden vernietigt, en uiteindelijk het vermogen om de eenvoudigste taken uit te voeren., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05323812 / 2021-003164-27: ASURE: Alzheimer Study Using oRal Edaravone

Completed
2
61
Europe, RoW
TW001, Edaravone, Placebo
Treeway B.V., Treeway TW001AD B.V.
Alzheimer Disease
12/24
12/24
apomorphine inhalational (AZ-009) / Ferrer International
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24

Download Options